Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab

Leukemia. 2022 May;36(5):1426-1428. doi: 10.1038/s41375-021-01501-0. Epub 2022 Jan 29.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal*
  • Humans
  • Mass Spectrometry
  • Multiple Myeloma*

Substances

  • Antibodies, Monoclonal
  • daratumumab